ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1751

Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

Anca Askanase1, Simrat Randhawa2, Laura Lisk3 and Paola Mina-Osorio4, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals Inc., Seattle, WA, 3Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, 4Aurinia Pharmaceuticals Inc., New York, NY

Meeting: ACR Convergence 2021

Keywords: clinical trial, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: SLE – Treatment Poster (1732–1772)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy. Voclosporin has a favorable metabolic profile and a consistent dose-concentration relationship, eliminating the need for therapeutic drug monitoring. Pooled data from the similarly designed Phase 2 AURA-LV and the Phase 3 AURORA 1 trials demonstrated that compared with standard of care agents (mycophenolate mofetil [MMF] and low-dose steroids) alone, the addition of voclosporin resulted in higher complete renal response rates (CRR) at 24 weeks (31.7% vs 20.3%; odds ratio [OR] 2.01; p=0.0008) and one year (43.7% vs 23.3%; OR 2.76; p< 0.0001) of treatment in patients with lupus nephritis. This abstract reports CRR by biopsy class in the same pooled data.

Methods: AURA-LV and AURORA 1 enrolled patients with a diagnosis of systemic lupus erythematosus according to ACR criteria, biopsy-proven active lupus nephritis (Class III, IV, or V ± III/IV) and proteinuria of ≥1.5 mg/mg (≥2 mg/mg for Class V). Treatment randomization was stratified by biopsy class (Class V only vs Others) and by MMF use at screening. Pooled data included 268 patients in the voclosporin (23.7 mg BID) arm (89 from AURA-LV and 179 from AURORA 1) and 266 patients in the control arm (88 from AURA-LV and 178 from AURORA 1). All patients received MMF (1 g BID) and low-dose steroids (rapidly tapered to 2.5 mg/day at week 16). Though the trials were not powered to detect a significant difference between treatments groups by biopsy class, a post-hoc analysis of CRR by biopsy class subgroups was conducted.

Results: Demographic and clinical characteristics of the pooled population are shown in Table 1. The pooled analysis includes 79 (14.8%) patients with pure Class III, 253 (47.4%) with pure Class IV, 75 (14.0%) with pure Class V, and 127 (23.8%) with mixed Class V + III/IV lupus nephritis. The OR for CRR at one year in the voclosporin arm compared to control arm was 4.26 for pure Class III, 2.59 for pure Class IV, 1.50 for pure Class V, and 2.68 for mixed Class V + III/IV (Figure 1). Overall, 93.7% of patients in the voclosporin arm and 75.2% of patients in the control arm achieved ≥50% reduction from baseline in UPCR; the median time to ≥50% reduction in UPCR was 29 days for voclosporin arm and 58 days for the control arm (HR 1.96; log rank p< 0.0001; Figure 2). At 6 months, 83.2% of patients in the voclosporin arm and 85.0% of patients in the control arm were on ≤2.5 mg/day prednisone. At 12 months, 75.8% and 73.9% of patients in each arm, respectively, were on prednisone ≤2.5 mg/day.

Conclusion: Patients with lupus nephritis treated with voclosporin in addition to MMF and low-dose steroids had improved CRR rates (OR >1) across all biopsy class subgroups compared to the control arm, with the highest OR seen in pure Class III. This analysis further supports the efficacy of voclosporin and the critical need to consider lower doses of steroids in the treatment of lupus nephritis.

Table 1. Baseline and Demographic Characteristics

Figure 1. Complete Renal Response by Biopsy Class at One Year

Figure 2. Time to UPCR Reduction of ≥50%


Disclosures: A. Askanase, GSK, 2, 5, AstraZeneca, 1, 5, Amgen, 1, Aurinia, 2, Abbvie, 1, Pfizer, 5, Eli Lilly, 5, Idorsia, 5; S. Randhawa, Aurinia Pharmaceuticals Inc., 3, 11; L. Lisk, Aurinia Pharmaceuticals Inc., 3, 11; P. Mina-Osorio, Aurinia Pharmaceuticals Inc., 3, 11.

To cite this abstract in AMA style:

Askanase A, Randhawa S, Lisk L, Mina-Osorio P. Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/voclosporin-is-effective-in-achieving-complete-renal-response-across-lupus-nephritis-biopsy-classes-pooled-data-from-the-aura-lv-and-aurora-1-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/voclosporin-is-effective-in-achieving-complete-renal-response-across-lupus-nephritis-biopsy-classes-pooled-data-from-the-aura-lv-and-aurora-1-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology